Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 113

1.

Accurate assessment of HER2 gene status for invasive component of breast cancer by combination of immunohistochemistry and chromogenic In Situ hybridization.

Nie X, He J, Li Y, Pan DZ, Pan HX, Weng MX, Yang XP, Liu CP, Huang T.

J Huazhong Univ Sci Technolog Med Sci. 2013 Jun;33(3):379-84. doi: 10.1007/s11596-013-1128-5. Epub 2013 Jun 17.

PMID:
23771664
[PubMed - indexed for MEDLINE]
2.

Determination of HER2/neu status: a pilot study comparing HER2/neu dual in situ hybridization DNA probe cocktail assay performed on cell blocks to immunohistochemisty and fluorescence in situ hybridization performed on histologic specimens.

Hartman AK, Gorman BK, Chakraborty S, Mody DR, Schwartz MR.

Arch Pathol Lab Med. 2014 Apr;138(4):553-8. doi: 10.5858/arpa.2013-0314-SA.

PMID:
24678687
[PubMed - indexed for MEDLINE]
3.

Chromogenic in situ hybridization (CISH) to detect HER2 gene amplification in breast and gastric cancer: comparison with immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH).

Kiyose S, Igarashi H, Nagura K, Kamo T, Kawane K, Mori H, Ozawa T, Maeda M, Konno K, Hoshino H, Konno H, Ogura H, Shinmura K, Hattori N, Sugimura H.

Pathol Int. 2012 Nov;62(11):728-34. doi: 10.1111/j.1440-1827.2012.02862.x.

PMID:
23121603
[PubMed - indexed for MEDLINE]
4.

Validation and workflow optimization of human epidermal growth factor receptor 2 testing using INFORM HER2 dual-color in situ hybridization.

Lim SJ, Cantillep A, Carpenter PM.

Hum Pathol. 2013 Nov;44(11):2590-6. doi: 10.1016/j.humpath.2013.07.005. Epub 2013 Sep 25.

PMID:
24075600
[PubMed - indexed for MEDLINE]
5.

PGDS, a novel technique combining chromogenic in situ hybridization and immunohistochemistry for the assessment of ErbB2 (HER2/neu) status in breast cancer.

Ni R, Mulligan AM, Have C, O'Malley FP.

Appl Immunohistochem Mol Morphol. 2007 Sep;15(3):316-24.

PMID:
17721278
[PubMed - indexed for MEDLINE]
6.

Her2 amplification: correlation of chromogenic in situ hybridization with immunohistochemistry and fluorescence in situ hybridization.

Wixom CR, Albers EA, Weidner N.

Appl Immunohistochem Mol Morphol. 2004 Sep;12(3):248-51.

PMID:
15551739
[PubMed - indexed for MEDLINE]
7.

Determination of HER2 gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma.

Zhao J, Wu R, Au A, Marquez A, Yu Y, Shi Z.

Mod Pathol. 2002 Jun;15(6):657-65.

PMID:
12065780
[PubMed - indexed for MEDLINE]
Free Article
8.

Comparison of different commercial kits for HER2 testing in breast cancer: looking for the accurate cutoff for amplification.

Cayre A, Mishellany F, Lagarde N, Penault-Llorca F.

Breast Cancer Res. 2007;9(5):R64.

PMID:
17908324
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

HER2 evaluation using the novel rabbit monoclonal antibody SP3 and CISH in tissue microarrays of invasive breast carcinomas.

Ricardo SA, Milanezi F, Carvalho ST, Leitão DR, Schmitt FC.

J Clin Pathol. 2007 Sep;60(9):1001-5. Epub 2006 Dec 8.

PMID:
17158643
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Evaluation of dual immunohistochemistry and chromogenic in situ hybridization for HER2 on a single section.

Reisenbichler ES, Horton D, Rasco M, Andea A, Hameed O.

Am J Clin Pathol. 2012 Jan;137(1):102-10. doi: 10.1309/AJCPLNHINN9O6YSF.

PMID:
22180483
[PubMed - indexed for MEDLINE]
Free Article
11.

[Comparision of HER2/neu oncogene detected by chromogenic in-situ hybridization and immunohistochemistry in breast cancer].

Zhang GH, Shi DR, Liang XM, Hou JH, Kang SY, Zhu WD, Li XB, Shao Y, Chen LR, Zhou Y.

Zhonghua Bing Li Xue Za Zhi. 2006 Oct;35(10):580-3. Chinese.

PMID:
17134562
[PubMed - indexed for MEDLINE]
12.

Role of chromogenic in situ hybridization (CISH) in the evaluation of HER2 status in breast carcinoma: comparison with immunohistochemistry and FISH.

Li-Ning-T E, Ronchetti R, Torres-Cabala C, Merino MJ.

Int J Surg Pathol. 2005 Oct;13(4):343-51.

PMID:
16273190
[PubMed - indexed for MEDLINE]
13.

Dual-colour chromogenic in-situ hybridization is a potential alternative to fluorescence in-situ hybridization in HER2 testing.

Hwang CC, Pintye M, Chang LC, Chen HY, Yeh KY, Chein HP, Lee N, Chen JR.

Histopathology. 2011 Nov;59(5):984-92. doi: 10.1111/j.1365-2559.2011.04037.x.

PMID:
22092410
[PubMed - indexed for MEDLINE]
14.

[Analysis of HER2 gene amplification and its protein expression in 165 cases of breast carcinoma: comparison of chromogenic in-situ hybridization and immunohistochemistry].

Shen DH, Wang FH, Yu YZ.

Zhonghua Bing Li Xue Za Zhi. 2007 Jul;36(7):457-60. Chinese.

PMID:
17845758
[PubMed - indexed for MEDLINE]
15.

Chromogenic in situ hybridisation for the assessment of HER2 status in breast cancer: an international validation ring study.

van de Vijver M, Bilous M, Hanna W, Hofmann M, Kristel P, Penault-Llorca F, Rüschoff J.

Breast Cancer Res. 2007;9(5):R68.

PMID:
17922920
[PubMed - indexed for MEDLINE]
Free PMC Article
16.
17.

Detection of human epidermal growth factor receptor 2 protein and gene in fine needle aspiration cytology specimens and tissue sections from invasive breast cancer: can cytology specimens take the place of tissue sections?

Sumiyoshi K, Shibayama Y, Akashi S, Nohara T, Iwamoto M, Kobayashi T, Nishimura H, Yoshinaka R, Harada T, Tanigawa N.

Oncol Rep. 2006 Apr;15(4):803-8.

PMID:
16525662
[PubMed - indexed for MEDLINE]
18.

HER-2/neu amplification testing in breast cancer by multiplex ligation-dependent probe amplification in comparison with immunohistochemistry and in situ hybridization.

Moelans CB, de Weger RA, van Blokland MT, Ezendam C, Elshof S, Tilanus MG, van Diest PJ.

Cell Oncol. 2009;31(1):1-10.

PMID:
19096145
[PubMed - indexed for MEDLINE]
19.

Calibration of immunohistochemistry for assessment of HER2 in breast cancer: results of the French multicentre GEFPICS study.

Vincent-Salomon A, MacGrogan G, Couturier J, Arnould L, Denoux Y, Fiche M, Jacquemier J, Mathieu MC, Penault-Llorca F, Rigaud C, Roger P, Treilleux I, Vilain MO, Mathoulin-Pélissier S, Le Doussal V.

Histopathology. 2003 Apr;42(4):337-47.

PMID:
12653945
[PubMed - indexed for MEDLINE]
20.

[Analysis of HER2 status in breast carcinoma using fully automated HER2 staining and fluorescence in-situ hybridization technology].

Ying JM, Liu XY, Guo L, Xie YQ, Lü N.

Zhonghua Bing Li Xue Za Zhi. 2012 May;41(5):296-300. doi: 10.3760/cma.j.issn.0529-5807.2012.05.003. Chinese.

PMID:
22883666
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk